Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Classic paraneoplastic limbic encephalitis is a rare neuroimmunological disorder characterized by the sudden onset of seizures, progressive memory impairment (which may develop into dementia) and psychiatric manifestations (e.g. depression, personality changes, loss of social inhibition) associated with cancer (most commonly small-cell carcinoma of the lung) in the absence of tumor cell invasion of the nervous system. Other reported features include ataxia, dystonia, paresthesia, tremors, paranoid ideation, and hallucinations. The presence of antibodies that act on neuronal antigens (such as anti-Hu, anti-Ma2, anti-amphiphysin) are typically observed.
Biomarker and diagnostic research for classic paraneoplastic limbic encephalitis has been reported in the published literature.
No clinical trials have been registered for classic paraneoplastic limbic encephalitis.
153 publications have been identified in PubMed for classic paraneoplastic limbic encephalitis. Research spans Basic Science / Preclinical (86%), Gene Therapy / Novel Therapeutics (6%), and Diagnostic / Biomarker (3%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 132 | 86% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 10:49 PM UTC
European rare disease database
Common questions about classic paraneoplastic limbic encephalitis
New treatment approaches
9 |
6% |
Testing and diagnosis research | 4 | 3% |
Research summaries | 4 | 3% |
Patient case studies | 3 | 2% |
Clinical study results | 1 | 1% |
Merlino F (2026). [PMID: 41729103](https://pubmed.ncbi.nlm.nih.gov/41729103/). *J Med Chem*. [Gene Therapy / Novel Therapeutics]
Zhang R (2026). [PMID: 41526167](https://pubmed.ncbi.nlm.nih.gov/41526167/). *J Immunother Cancer*. [Basic Science / Preclinical]
Wan WH (2026). [PMID: 41680445](https://pubmed.ncbi.nlm.nih.gov/41680445/). *Nat Cell Biol*. [Basic Science / Preclinical]
Chemla Y (2026). [PMID: 41401806](https://pubmed.ncbi.nlm.nih.gov/41401806/). *Cell*. [Basic Science / Preclinical]
Zhang H (2026). [PMID: 41556583](https://pubmed.ncbi.nlm.nih.gov/41556583/). *Autophagy*. [Basic Science / Preclinical]
Wang J (2026). [PMID: 41748561](https://pubmed.ncbi.nlm.nih.gov/41748561/). *Nat Commun*. [Basic Science / Preclinical]
Song H (2026). [PMID: 41861782](https://pubmed.ncbi.nlm.nih.gov/41861782/). *Cell*. [Basic Science / Preclinical]
Zhu L (2026). [PMID: 41435838](https://pubmed.ncbi.nlm.nih.gov/41435838/). *Mol Cell*. [Basic Science / Preclinical]
Altabakhi I (2026). [PMID: 30137808](https://pubmed.ncbi.nlm.nih.gov/30137808/). *Unknown Journal*. [Basic Science / Preclinical]
Huang Y (2026). [PMID: 41221601](https://pubmed.ncbi.nlm.nih.gov/41221601/). *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*. [Basic Science / Preclinical]